Original Publication Date: >1 June, 2016
Publication / Source: Neurodegenerative Disease Management
Authors: Jofre Güell-Bosch, Laia Montoliu-Gaya, Gisela Esquerda-Canals & Sandra Villegas
Alzheimer’s disease (AD) was implicated in most of the estimated 46.8 million worldwide dementia cases in 2015, with projections set to almost triple by 2050 . Because current therapies are focused on ameliorating AD symptoms instead of targeting the underlying causes of the disease, it is necessary to develop disease-modifying therapies.